Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Assets (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Non-Current Assets data on record, last reported at -$288.3 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 672.13% year-over-year to -$288.3 million; the TTM value through Sep 2025 reached -$697.4 million, up 24.74%, while the annual FY2024 figure was $44.3 million, 19.46% down from the prior year.
  • Non-Current Assets reached -$288.3 million in Q3 2025 per ZNTL's latest filing, down from $44.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $95.3 million in Q3 2022 and bottomed at -$528.3 million in Q3 2023.
  • Average Non-Current Assets over 4 years is -$188.0 million, with a median of -$122.0 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: soared 112.16% in 2023, then crashed 672.13% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at -$451.9 million in 2022, then soared by 112.16% to $55.0 million in 2023, then fell by 19.46% to $44.3 million in 2024, then crashed by 751.22% to -$288.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$288.3 million in Q3 2025, $44.3 million in Q4 2024, and $50.4 million in Q3 2024.